Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial

Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab effica...

Descripción completa

Detalles Bibliográficos
Autores: Blauvelt, A, Langley, RG, Lebwohl, M, Strober, B, Warren, RB, Puig, L, Morita, A, Gordon, KB, Fernandez-Peña, P, Kavanagh, S, Pinto, JML, Lambert, J, Hoepken, B, Deherder, D, Cross, N, Thaçi, D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p20532
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532
Access Level:acceso abierto
Palabra clave:bimekizumab
efficacy
long-term
plaque psoriasis
psoriasis
quality of life
safety
id ES_eb738fea6bfdfec905e2fbcf0fc58e8c
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p20532
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialBlauvelt, ALangley, RGLebwohl, MStrober, BWarren, RBPuig, LMorita, AGordon, KBFernandez-Peña, PKavanagh, SPinto, JMLLambert, JHoepken, BDeherder, DCross, NThaçi, Dbimekizumabefficacylong-termplaque psoriasispsoriasisquality of lifesafetyBackground: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. Methods: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received $1 bimekizumab dose. Results: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64. 7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. Limitations: Eligibility criteria and ethnic representation. Conclusion: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option.MOSBY-ELSEVIER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGYISSN: 01909622ISSNe: 10976787reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p205322026-06-14T12:41:47Z
dc.title.none.fl_str_mv Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
title Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
spellingShingle Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt, A
bimekizumab
efficacy
long-term
plaque psoriasis
psoriasis
quality of life
safety
title_short Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
title_full Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
title_fullStr Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
title_full_unstemmed Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
title_sort Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
dc.creator.none.fl_str_mv Blauvelt, A
Langley, RG
Lebwohl, M
Strober, B
Warren, RB
Puig, L
Morita, A
Gordon, KB
Fernandez-Peña, P
Kavanagh, S
Pinto, JML
Lambert, J
Hoepken, B
Deherder, D
Cross, N
Thaçi, D
author Blauvelt, A
author_facet Blauvelt, A
Langley, RG
Lebwohl, M
Strober, B
Warren, RB
Puig, L
Morita, A
Gordon, KB
Fernandez-Peña, P
Kavanagh, S
Pinto, JML
Lambert, J
Hoepken, B
Deherder, D
Cross, N
Thaçi, D
author_role author
author2 Langley, RG
Lebwohl, M
Strober, B
Warren, RB
Puig, L
Morita, A
Gordon, KB
Fernandez-Peña, P
Kavanagh, S
Pinto, JML
Lambert, J
Hoepken, B
Deherder, D
Cross, N
Thaçi, D
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv bimekizumab
efficacy
long-term
plaque psoriasis
psoriasis
quality of life
safety
topic bimekizumab
efficacy
long-term
plaque psoriasis
psoriasis
quality of life
safety
description Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. Methods: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received $1 bimekizumab dose. Results: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64. 7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. Limitations: Eligibility criteria and ethnic representation. Conclusion: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MOSBY-ELSEVIER
publisher.none.fl_str_mv MOSBY-ELSEVIER
dc.source.none.fl_str_mv JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN: 01909622
ISSNe: 10976787
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423228681715712
score 15,81155

Similares en LA Referencia